Research progress of sorafenib in tumor therapy
Discussion of Clinical Cases · 2015
DOI: 10.14725/dcc.v2n3p41 ↗Kurz gefasst
Fachartikel in der Zeitschrift Discussion of Clinical Cases, 2015. Verfasst von Huijie Zhang und 1 weiteren Autor:innen.
Abstract (Originalsprache)
Multi-kinase inhibitor Sola Fini (sorafenib), as the first approved multi-target agent, is a noval multi-target signal transduction inhibitors, which can inhibit the proliferation of tumor cells, prevent tumor angiogenesis and induce apoptosis of tumor cells. Studies have shown that Sola Fini imposes extensive antitumor activity on animal model of human tumor xenograft, such as mouse renal cell carcinoma, colon cancer, pancreatic cancer, thyroid cancer, non-small cell lung cancer, breast cancer and ovarian cancer model. In this paper, the mechanism of anti-tumor of sorafenib and the progress of tumor therapy are reviewed.
Zitieren
APA
Zhang, H., & Guo, W. (2015). Research progress of sorafenib in tumor therapy. Discussion of Clinical Cases. https://doi.org/10.14725/dcc.v2n3p41
Vancouver
Zhang H, Guo W. Research progress of sorafenib in tumor therapy. Discussion of Clinical Cases. 2015. doi:10.14725/dcc.v2n3p41
BibTeX
@article{Zhang2015,
author = {Zhang, Huijie and Guo, Weidong},
title = {Research progress of sorafenib in tumor therapy},
journal = {Discussion of Clinical Cases},
year = {2015},
doi = {10.14725/dcc.v2n3p41}
}
EUVIMED